{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:09:03Z","timestamp":1791133743671,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.hoc.2012.03.002","type":"journal-article","created":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T18:10:19Z","timestamp":1334945419000},"page":"507-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Topoisomerase 1 Inhibitors and Cancer Therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Julia","family":"Moukharskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Verschraegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2012.03.002_bib1","first-page":"753","article-title":"Camptothecin and taxol: discovery to clinic. Thirteenth Bruce F. Cain Memorial Award Lecture","volume":"55","author":"Wall","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0022-2836(71)90334-2","article-title":"Interaction between DNA and an Escherichia coli protein omega","volume":"55","author":"Wang","year":"1971","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.hoc.2012.03.002_bib3","doi-asserted-by":"crossref","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","article-title":"Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I","volume":"260","author":"Hsiang","year":"1985","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.hoc.2012.03.002_bib4","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.84.20.7024","article-title":"Supercoiling of the DNA template during transcription","volume":"84","author":"Liu","year":"1987","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2012.03.002_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.hoc.2012.03.002_bib6","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1021\/cr900097c","article-title":"DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition","volume":"109","author":"Pommier","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.hoc.2012.03.002_bib7","doi-asserted-by":"crossref","first-page":"8752","DOI":"10.1158\/0008-5472.CAN-06-4554","article-title":"Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses","volume":"67","author":"Miao","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib8","first-page":"1431","article-title":"Camptothecins: from bench research to hospital wards","volume":"54","author":"Potmesil","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib9","first-page":"5077","article-title":"Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin","volume":"49","author":"Hsiang","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib10","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.279.5356.1534","article-title":"A\u00a0model for the mechanism of human topoisomerase I","volume":"279","author":"Stewart","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.hoc.2012.03.002_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0167-4781(98)00129-8","article-title":"Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme","volume":"1400","author":"Pommier","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.hoc.2012.03.002_bib12","doi-asserted-by":"crossref","first-page":"21074","DOI":"10.1074\/jbc.M803493200","article-title":"A\u00a0ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes","volume":"283","author":"Lin","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.hoc.2012.03.002_bib13","first-page":"1465","article-title":"Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity","volume":"49","author":"Jaxel","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0006-2952(85)90499-X","article-title":"Action of camptothecin and its derivatives on deoxyribonucleic acid","volume":"34","author":"Fukada","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/17425247.2.2.323","article-title":"Alternative administration of camptothecin analogues","volume":"2","author":"Glaberman","year":"2005","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.hoc.2012.03.002_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.1996.tb26372.x","article-title":"Synthesis of CPT-11 (irinotecan hydrochloride trihydrate)","volume":"803","author":"Sawada","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.hoc.2012.03.002_bib17","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1016\/S0040-4020(03)01203-1","article-title":"Towards new anticancer drugs: a decade of advances in synthesis of camptothecins and related alkaloids","volume":"59","author":"Du","year":"2003","journal-title":"Tetrahedron"},{"key":"10.1016\/j.hoc.2012.03.002_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bcp.2007.10.016","article-title":"Next generation topoisomerase I inhibitors: rationale and biomarker strategies","volume":"75","author":"Teicher","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib19","doi-asserted-by":"crossref","first-page":"10325","DOI":"10.1021\/bi00200a013","article-title":"Differential interactions of camptothecin lactone and carboxylate forms with human blood components","volume":"33","author":"Mi","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.hoc.2012.03.002_bib20","doi-asserted-by":"crossref","first-page":"13722","DOI":"10.1021\/bi00042a002","article-title":"Reduced albumin binding promotes the stability and activity of topotecan in human blood","volume":"34","author":"Mi","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.hoc.2012.03.002_bib21","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib22","first-page":"6330","article-title":"Kinetics of the in\u00a0vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients","volume":"54","author":"Rivory","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.hoc.2012.03.002_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/sj.bjc.6690364","article-title":"CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues","volume":"80","author":"Guichard","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib25","first-page":"1261","article-title":"Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I\/II trials","volume":"3","author":"Rivory","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib26","first-page":"6921","article-title":"Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis","volume":"60","author":"Ando","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/path.2766","article-title":"Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application","volume":"223","author":"Lee","year":"2011","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.hoc.2012.03.002_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2012.03.002_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2165\/00003088-199733010-00003","article-title":"The role of beta-glucuronidase in drug disposition and drug targeting in humans","volume":"33","author":"Sperker","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.hoc.2012.03.002_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/1078-0432.CCR-09-2936","article-title":"Individualizing dosing of irinotecan","volume":"16","author":"Ratain","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/bjc.1997.491","article-title":"Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development","volume":"76","author":"Gerrits","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.03.002_bib33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2012.03.002_bib34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2012.03.002_bib35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00384-002-0464-x","article-title":"A\u00a0pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma","volume":"18","author":"Muhr-Wilkenshoff","year":"2003","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.hoc.2012.03.002_bib36","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib37","first-page":"103","article-title":"Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers","volume":"12","author":"Rosen","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.hoc.2012.03.002_bib38","first-page":"32","article-title":"Irinotecan for the treatment of cervical cancer","volume":"16","author":"Verschraegen","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.hoc.2012.03.002_bib39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdj137","article-title":"A\u00a0randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer","volume":"17","author":"Schmittel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib40","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2012.03.002_bib41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0731-7085(90)80102-U","article-title":"Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution","volume":"8","author":"Underberg","year":"1990","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.hoc.2012.03.002_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1568009023333890","article-title":"Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan","volume":"2","author":"Mathijssen","year":"2002","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.hoc.2012.03.002_bib43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s002800050605","article-title":"Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan","volume":"39","author":"Rosing","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib44","first-page":"A2198","article-title":"A\u00a0phase I study of intrathecal topotecan","volume":"39","author":"Blaney","year":"1998","journal-title":"Proc Am Assoc Canc Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1634\/theoncologist.9-1-68","article-title":"The role of topotecan in the treatment of brain metastases","volume":"9","author":"Wong","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.hoc.2012.03.002_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjc.6604835","article-title":"A\u00a0phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer","volume":"100","author":"Neuhaus","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib47","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/1471-2407-10-436","article-title":"Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer","volume":"10","author":"Riemsma","year":"2010","journal-title":"BMC Cancer"},{"issue":"Suppl 6","key":"10.1016\/j.hoc.2012.03.002_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.9-90006-25","article-title":"Emerging role of weekly topotecan in recurrent small cell lung cancer","volume":"9","author":"Eckardt","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.hoc.2012.03.002_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ygyno.2011.04.020","article-title":"Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown","volume":"122","author":"Markman","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib51","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib52","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"23","author":"Long","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib53","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1023\/A:1008393512479","article-title":"A\u00a0dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer","volume":"11","author":"Sorensen","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/gyno.2000.6024","article-title":"A\u00a0phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"81","author":"Muderspach","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","article-title":"Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"31","author":"Beran","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2012.03.002_bib56","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2007.10.9298","article-title":"Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study","volume":"25","author":"Metzger","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0169-5002(99)00128-2","article-title":"A\u00a0randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer","volume":"28","author":"Weitz","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib58","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2005.12.003","article-title":"Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study","volume":"102","author":"Rose","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib59","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00280-005-0091-7","article-title":"Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice","volume":"57","author":"Schluep","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-3659(99)00243-6","article-title":"Polymer-bound camptothecin: initial biodistribution and antitumour activity studies","volume":"65","author":"Caiolfa","year":"2000","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.hoc.2012.03.002_bib61","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.addr.2007.11.009","article-title":"Polymer-drug conjugates: recent development in clinical oncology","volume":"60","author":"Li","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.hoc.2012.03.002_bib62","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1200\/JCO.2003.03.143","article-title":"A\u00a0phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies","volume":"21","author":"Rowinsky","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib63","doi-asserted-by":"crossref","first-page":"A5013","DOI":"10.1200\/jco.2010.28.15_suppl.5013","article-title":"Phase II study of NKTR-102 in women with platinum-resistant\/refractory ovarian cancer","volume":"28","author":"Vergote","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib64","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1158\/1078-0432.CCR-06-2821","article-title":"Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies","volume":"13","author":"Homsi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib65","first-page":"499","article-title":"Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs","volume":"14","author":"Conover","year":"1999","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.hoc.2012.03.002_bib66","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1163\/156856207782177918","article-title":"Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors","volume":"18","author":"Ying","year":"2007","journal-title":"J\u00a0Biomater Sci Polym Ed"},{"key":"10.1016\/j.hoc.2012.03.002_bib67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-008-0746-2","article-title":"A\u00a0phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma","volume":"63","author":"Scott","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib68","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj070112","article-title":"Role of the breast cancer resistance protein (ABCG2) in drug transport","volume":"7","author":"Mao","year":"2005","journal-title":"AAPS J"},{"key":"10.1016\/j.hoc.2012.03.002_bib69","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in\u00a0vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.90140.2003","article-title":"Phase I and pharmacological study of oral topotecan and the BCRP and P-gp inhibitor elacridar","volume":"22","author":"Schellens","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib71","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Ame","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.hoc.2012.03.002_bib72","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/nar\/gki190","article-title":"Translocation of XRCC1 and DNA ligase IIIalpha from centrosomes to chromosomes in response to DNA damage in mitotic human cells","volume":"33","author":"Okano","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bmb\/ldp005","article-title":"The potential role and application of PARP inhibitors in cancer treatment","volume":"89","author":"Chalmers","year":"2009","journal-title":"Br Med Bull"},{"key":"10.1016\/j.hoc.2012.03.002_bib74","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1096\/fj.06-5916fje","article-title":"Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan\/temozolomide efficacy against colon carcinoma","volume":"20","author":"Tentori","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.hoc.2012.03.002_bib75","first-page":"683","article-title":"Topoisomerase-I inhibitors in gynaecologic tumours","volume":"27","author":"Verschraegen","year":"1998","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.hoc.2012.03.002_bib76","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1517\/13543770902773437","article-title":"Novel camptothecin derivatives as topoisomerase I inhibitors","volume":"19","author":"Basili","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.hoc.2012.03.002_bib77","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cncr.25710","article-title":"Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer","volume":"117","author":"Choi","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/cncr.24719","article-title":"Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2012.03.002_bib79","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00280-011-1689-6","article-title":"Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer","volume":"69","author":"Hong","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib80","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejca.2009.11.006","article-title":"Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels","volume":"46","author":"Frapolli","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib81","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bcp.2005.07.009","article-title":"The novel lipophilic camptothecin analogue gimatecan is very active in\u00a0vitro in human neuroblastoma: a comparative study with SN38 and topotecan","volume":"70","author":"Di Francesco","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib82","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/annonc\/mdp514","article-title":"Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes","volume":"21","author":"Pecorelli","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib83","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2165\/00003495-200262140-00004","article-title":"Camptothecins: a review of their chemotherapeutic potential","volume":"62","author":"Ulukan","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2012.03.002_bib84","first-page":"2903","article-title":"Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan","volume":"6","author":"Emerson","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib85","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2005.02.028","article-title":"Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada Clinical Trials group","volume":"23","author":"Dark","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib86","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/bjc.1997.490","article-title":"The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor","volume":"76","author":"Gerrits","year":"1997","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2012.03.002_bib87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00001813-199904000-00005","article-title":"A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer","volume":"10","author":"Verschraegen","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.hoc.2012.03.002_bib88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00001813-199801000-00004","article-title":"A\u00a0phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor","volume":"9","author":"Verschraegen","year":"1998","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.hoc.2012.03.002_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/B:DRUG.0000006176.84915.71","article-title":"A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer","volume":"22","author":"Miller","year":"2004","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.hoc.2012.03.002_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1634\/theoncologist.10-3-183","article-title":"Phase II trial of oral rubitecan in previously treated pancreatic cancer patients","volume":"10","author":"Burris","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.hoc.2012.03.002_bib91","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1078-0432.CCR-09-2429","article-title":"A\u00a0phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies","volume":"16","author":"Arnold","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2004.11.019","article-title":"Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)","volume":"48","author":"Miller","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib93","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1078-0432.CCR-04-1722","article-title":"Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study","volume":"11","author":"Daud","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib94","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/S0960-894X(99)00555-7","article-title":"Synthesis and in\u00a0vitro cytotoxicity of hexacyclic camptothecin analogues","volume":"9","author":"Jew","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.hoc.2012.03.002_bib95","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/jm970765q","article-title":"Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues","volume":"41","author":"Sugimori","year":"1998","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.hoc.2012.03.002_bib96","doi-asserted-by":"crossref","first-page":"15556","DOI":"10.1021\/bi990947h","article-title":"Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks","volume":"38","author":"Bailly","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.hoc.2012.03.002_bib97","first-page":"2939","article-title":"Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties","volume":"59","author":"Lesueur-Ginot","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib98","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1200\/JCO.2001.19.5.1493","article-title":"Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog","volume":"19","author":"Royce","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib99","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2006.07.0201","article-title":"Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2012.03.002_bib100","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cncr.11557","article-title":"A\u00a0Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma","volume":"98","author":"Esteva","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2012.03.002_bib101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00001813-200006000-00005","article-title":"Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6","volume":"11","author":"Ishii","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.hoc.2012.03.002_bib102","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.bmc.2010.03.039","article-title":"Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities","volume":"18","author":"Miao","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.hoc.2012.03.002_bib103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/13543780802571674","article-title":"Diflomotecan, a promising homocamptothecin for cancer therapy","volume":"18","author":"Kroep","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hoc.2012.03.002_bib104","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-006-0267-9","article-title":"A\u00a0phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors","volume":"59","author":"Hurwitz","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.hoc.2012.03.002_bib105","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1021\/jm801641t","article-title":"Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin","volume":"52","author":"Sunami","year":"2009","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.hoc.2012.03.002_bib106","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1021\/jm800259e","article-title":"Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors","volume":"51","author":"Cinelli","year":"2008","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.hoc.2012.03.002_bib107","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1158\/1078-0432.CCR-10-0542","article-title":"Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment","volume":"17","author":"Kurtzberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2012.03.002_bib108","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0968-0896(03)00051-8","article-title":"5H-Dibenzo[c, h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity","volume":"11","author":"Ruchelman","year":"2003","journal-title":"Bioorg Med Chem"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858812000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858812000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:57:22Z","timestamp":1760183842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858812000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0889858812000263"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2012.03.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topoisomerase 1 Inhibitors and Cancer Therapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2012.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}